Alkermes Announces Results From Phase 2 Study Of ALKS 33 In Alcohol Dependence
Alkermes, Inc. (NASDAQ: ALKS) announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes’ proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 …
Read more on Medical News Today
Community Briefs
Norma Carter, author of “Without Warning: Successfully Coping with Sudden Loss” will be the featured speaker at the Dec. 16 bereavement luncheon hosted by the Visiting Nurse Association. Carter will be speaking on coping with the holidays.
Read more on The Rowlett Lakeshore Times
